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Background  
The role of nurses and pharmacists in prescribing medicines has been expanding in 
recent years and the 8.¶Vcurrent model of prescribing is widely regarded as being 
at the international forefront (Latter, 2011). The original policy objectives for the 
development of non-medical prescribing (NMP) related to the principles set out in the 
NHS Plan (DH, 2000): improvements in patient care, choice and access, patient 
VDIHW\EHWWHUXVHRIKHDOWKSURIHVVLRQDOV¶VNLOOVDQGPRUHIOH[LEOHWHDPZRUNLQJ
across the NHS. In working towards these objectives the NHS embarked on a 
graduated move to increase the scope and responsibilities of non-medical 
prescribing culminating in the opening of the British National Formulary (BNF) to 
independent nurse and pharmacist prescribers in 2006 and legislative changes 
which enabled the prescribing of controlled drugs in 2012. There are now over 1,300 
pharmacists and over 18,000 nurse prescribers representing around 3% of the 
pharmacist and nursing workforce in England.  
Some of the benefits of NMP have been substantiated through research (Courtenay, 
2008, Carey and Stenner, 2011, Stenner and Courtenay, 2008) and non-medical 
prescribing continues to grow particularly in disease specific areas such as diabetes, 
asthma, hypertension and chronic obstructive airways disease. Several studies have 
identified that prescribing for patients with co-morbid conditions present challenges 
for non-medical prescribers, raising questions about the potential future impact of 
NMP within a healthcare system serving an increasing number of older people with 
multiple long term conditions.  
Previous research exploring NMP has focussed almost exclusively on the views of 
the prescribers (Latter 2011). This research highlights the importance of 
understanding the barriers and facilitator to implementing NMP practice within 
routine services. However, empirical studies are required illustrating the growth and 
impact of NMP because there is concern that NMP is being driven by individual 
practitioners rather than organisational strategy (Latter 2011). Only half of UK NHS 
Trusts have a strategy for the development of NMP (Latter 2010). One of the key 
recommendations of a national evaluation of NMP was that it is necessary to gather 
and disseminate empirical evidence to demonstrate the clinical and economic impact 
of NMP (Latter 2011). To date this has not been achieved, possibly due to the 
methodological challenges it presents. Establishing the extent of prescribing activity 
nationally or within a specific patient population is challenging. Although the UK 
Nursing and Midwifery Council and the General Pharamceutical Register both 
maintain a record of members who are qualified prescribers, they do not hold 
information about the clinical setting in which they work. It would seem logical that 
the annual growth in non-medical prescribing activity is proportionate to the annual 
growth in qualified prescribers but previous studies (Courtenay, 2010) have found 
that many qualified prescribers do not actually prescribe and in some settings such 
as palliative care, the number of qualified NMPs not prescribing is as high as 50% 
(Ryan-Woolley et al., 2008). This may in part be explained by palliative care being a 
particularly challenging speciality for NMPs due to many of the patients having 
complex comorbid conditions and a high prevalence of pain which until the legislative 
changes permitting the prescribing of controlled drugs, (DOH, 2012) NMPs were ill 
equipped to treat. These changes had the potential to transform the scope of NMP in 
palliative care and facilitate the delivery of effective comprehensive pain 
management - a central component of high quality end of life care. Palliative care 
patients are therefore a particularly interesting population in which to examine the 
impact and growth of NMP. 
This study aims to establish the level of NMP activity in palliative care settings 
across England and consider the likely overall contribution NMPs are making at a 
national level in this context in relation to medical prescribing.         
 
Methods 
Source of data   
This study uses data derived from the Prescribing Analysis Cost Tool (PACT) system 
which is maintained by NHS Prescription Services and covers prescriptions 
prescribed by GPs, nurses and pharmacists in England and dispensed in the 
community. Prescriptions issued by non-medical prescribers are identifiable by a 
unique prescriber code. The PACT system does not indicate the specific clinical 
setting within community care in which the prescriber is working. We therefore 
devised a methodological approach which used drugs specific to palliative care 
settings and prescriber codes to identify prescriptions most likely to have been 
issued in palliative care by both medical and non-medical prescribers.       
 
Non-analgesic Palliative care prescriptions  
We worked with clinicians and pharmacists with palliative care expertise to identify a 
core list of drugs used almost exclusively in palliative care settings and are within the 
prescribgin comeptencies for NMPs. The core list of drugs comprised Haloperidol, 
Hyoscine Butylbromide, Hyoscine Hydrobromide, and Levomepromazine or 
Levomepromazine Maleate.  
 
Opioids  
Opioids are the mainstay of pain management in palliative care (Gagnon et al., 
2015) however they are also used in the management of chronic non cancer pain. 
To calculate the proportion of all opioid prescriptions issued that were attributable to 
prescribing in a palliative care context we were guided by research evidence from a 
large recent cross sectional study which showed that 87.8% of prescriptions for the 
opioids  buprenorphine, fentanyl, morphine and oxycodone were for chronic pain (Zin 
et al., 2014). Therefore  these four drugs were added to our core list of palliative care 
drugs. We assigned 12% of the total number of medic issued prescriptions for these 
drugs to palliative care prescribing. Diamorphine was the final opioid added to the 
core list of palliative care drugs as it is the second most commonly used pain relief 
drug in the end of life care (Higginson and Gao, 2012). Diamorphine prescriptions 
were exempt from the adjustments made to the other four analgesics as it is not 
typically used for chronic pain management.  
 
Data extraction  
All prescriptions for any of the 12 items in the core list of palliative care drugs and 
prescribed by NHS organisations in England and dispensed in the community in the 
UK between April 2011 and April 2015 were extracted from the PACT system by the 
Health and Social Care Information Centre in September 2015. The data was broken 
down by prescriber (medical prescribers, nurse prescribers and pharmacist 
prescribers). Prescriptions written in England but dispensed outside England are 
included. Prescriptions written in hospitals or outpatient clinics that are dispensed in 
the community, prescriptions dispensed in hospitals, dental prescribing and private 
prescriptions are not included in PACT data. 
 
Analysis  
It was intended that the prescribing activity for nurses and pharmacists would be 
evaluated separately. However, due to low numbers of prescriptions issued by 
pharmacists both they were group with nurse prescriptions and the combined group 
ODEHOHG³103´Basic descriptive analysis of prescription frequencies are presented 
by opioid, non-opioids and total prescriptions by year. To evaluate the yearly 
increase of NMP in relation to medical prescribing the total number of prescriptions 
were compared by year for each prescribing group (NMP versus medical). Overall 
changes in the proportion of opioid prescribing compared to non-opioid prescribing 
between 2011 and 2015 are presented descriptively by prescriber group. To 
evaluate the whether changes in prescription prevalence were associated with 
analgesic or non-analgesic prescriptions we separated the non-opioid palliative care 
prescriptions (Haloperidol, Hyoscine Butylbromide, Hyoscine Hydrobromide, 
Levomeprom Maleate and Levomepromazine) from the opioid (buprenorphine, 
fentanyl, morphine and oxycodone, diamorphine) prescriptions issued by NMPs and 
summarised the number of prescriptions issued for each group year on year  
 
Results 
 
Number of prescriptions issued  
 
Table 1 shows the number of prescriptions issued in palliative care between 2011 
and 2015.  The total number of prescriptions issued by both medical and non- 
medical prescribers increased by 25% from 1.2 million  to 1.6 million over the four 
year period. The number of prescriptions issued by nurse prescribers in the same 
time period has more than doubled from 50,492 in 2011 to 106,462 in 2015. 
The average annual increase in NMP issued prescriptions was 28% compared to an 
average annual increase of 9% in prescriptions issued by medics. Despite this, the 
annual growth in NMP was less than 1% a year in relation to total community 
palliative care prescribing activity in England. By 2015 NMPs were responsible for 
6.7% of all prescriptions issued in community palliative care compared with 4.2% in 
2011.    
 
 
 
 
Types of drugs prescribed 
 
 The yearly total of anagesic and non-analgesic prescrition are presented in Figure1.  
The total number of opioid prescriptions issued increased approximately 30% each 
year; (31% 2012-2013; 28% 2013-2014; and 33% 2014-2015. The number of non-
opioid prescriptions issued by non-medical prescribers showed a similar trend 
initially with a 32% increase between 2012 and 2013. For subsequent years however 
the rate of increase slowed with a 12% increase between 2013 and 2014 and a 10% 
increase between 2014 and 2015. This illustrates that the growth in total 
prescriptions issued by non-medical prescribers over the 2011-2015 period is almost 
entirely attributable to an increase in opioid prescriptions.  
We explored whether medical prescribing had followed the same trend. Figure 2 
illustrates that in 2011 opioids accounted for approximately 66% of prescriptions 
issued by both medical and non-medical prescribers. For medical prescribers this 
proportion remained stable (rising 1% to 67% in 2015) whereas for non-medical 
prescribers by 2015 opioids represented 76% of their overall prescribing activity.   
 
 
Discussion  
 
This study set out to address a stated need (Scrafton et al., 2012, Creedon et al., 
2015) for data to establish the level of NMP activity at a national level and consider 
the likely overall contribution NMPs are making in relation to medical prescribing. To 
the best of our knowledge no previous studies have attempted to quantify prescribing 
longitudinally in a specific patient population and consequently it was necessary to 
design and pilot a methodological approach to achieve this. The approach we have 
taken could be adapted using Dµcore list RIGUXJV¶VSHFLILFWRRWKHUSDWLHQW
populations to determine the extent of NMP in other contexts.  
 
We have identified that a year on year growth in the number of prescriptions issued 
by non-medical prescribers in palliative care. However, the proportion of NMPs 
issued in relation to medical prescribing remains relatively small. At the current rate 
of growth it will be 20 years before non-medical prescribers are prescribing 25% of 
all drugs issued in community palliative care.  
The number of opioid prescriptions issued by non-medical prescribers started to 
increase following the 2012 legislative changes (DOH, 2012) which permitted NMPs 
to prescribe controlled drugs, previously NMPs were only able to prescribe these 
drugs with the oversight of a medical colleague. The growth in opioid prescribing 
suggests NMPs have fully embraced the opportunity. NMP issued prescriptions for 
non-opioid medications have remained relatively stable over the same time period. 
This may simply reflect the fact that pain is the most prevalent symptom in end of life 
care (Gagnon et al., 2015) and as NMPs are now able to prescribe appropriate 
medication to manage it, it follows that it is likely to constitute a growing proportion of 
their prescribing activity.   
In terms of the impact of NMP on patient care, we have considered whether our data 
can determine if NMP could contribute to the national objective of improving pain 
control at the end of life  (NICE, 2012)? The original policy objectives of 
implementing NMP (DOH, 2006) were to  enable faster more responsive access to 
medications and relieve the prescribing burden from medical colleagues. Whilst this 
study cannot determine whether NMP has influenced the timing of access to 
medication, our data provides empirical evidence to demonstrate NMPs are 
prescribing the full range of drugs at their disposal and supports the finding of 
previous studies into the benefits of the NMP role in palliative care and other 
healthcare contexts (Ziegler et al., 2015, Stenner and Courtenay, 2008, Stenner et 
al., 2011). It is therefore reasonable to conclude that NMP activity positively 
contributes to improved pain control at the end of life.   
In terms of whether NMP is relieving the prescribing burden borne by medical 
colleagues, our data indicate that NMP is taking over from medical prescribing 
activity in palliative care at a rate of 1% each year. Impact on medical prescribing (in 
terms of number of prescriptions issued) is therefore minimal and the ability to 
increase this impact is made more difficult by the current growth in the palliative care 
population which creates an ever increasing demand for prescriptions.           
 
It is arguable whether the number of prescriptions issued provides an accurate 
reflection on the impact of the NMP¶VUROH(DUOLHUVWXGLHV (Ziegler et al., 2015, Ryan-
Woolley et al., 2007) have found that the role of non-medical prescribers working in 
palliative care extends beyond issuing prescriptions. Prescribers reported a 
significant proportion of µSUHVFULELQJ¶WLPHLVVSHQWUHYLHZLQJDQGUDWLRQDOLVLQJFXUUHQW
medication, discontinuing drugs and titrating doses. Polypharmacy is common in end 
of life care and minimising adverse effects by reviewing and discontinuing 
unnecessary or contraindicated medication is an important NMP activity which our 
data does not to capture.  
 
Conclusions  
 
Until now we have relied on local service level audits of NMP prescribing practice to 
chart the growth in prescribing activity which is often used as evidence of successful 
implementation and impact of NMP and provides justification for further service level 
investment. This study demonstrates for the first time that although a growth in NMP 
is evident, the number of prescriptions issued remains small in relation to medical 
prescribing. NMPs are prescribing the full range of drugs and proportionately more 
opioids than doctors. This suggests that although their impact in terms of numbers of 
prescriptions issued is small, the mainstay of their prescribing activity is pain 
management which is of crucial importance in end of life care.  
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Figure 1 Prescribing activity by non-medical prescribers 2011-2015   
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Figure 2; Proportion of opioid prescribing undertaken by NMPs and medical 
prescribers during 2011 and 2015 
 
         
 
Table 1 ± Palliative care prescribing activity 2011-2015: comparing medical and non-medical prescribers. 
 
Year 
 
2011/2012 2012/2013 2013/2014 2014/2015 
Parameter Medical  NMP All Medical  NMP All Medical  NMP All Medical  NMP All 
Buprenorphine 152,828 5,264 158,092 167,537 7,113 174,650 185,912 10,627 196,539 208,675 14,716 223,391 
Diamorphine 113,309 4,876 118,185 113,857 5,518 119,375 109,692 5,362 115,054 114,088 5,556 119,644 
Fentanyl 128,746 5,694 134,440 133,692 6,731 140,423 139,850 8,123 147,973 143,426 11,061 154,487 
Haloperidol 28,803 1,567 30,370 32,706 1,955 34,661 37,445 2,331 39,776 43,844 2,769 46,613 
Hyoscine 
Butylbromide 
35,701 1,580 37,281 41,806 2,207 44,013 47,470 2,575 50,045 58,230 3,098 61,328 
Hyoscine 
Hydrobromide 
32,012 1,560 33,572 35,374 1,809 37,183 34,763 1,922 36,685 31,655 1,768 33,423 
Levomeprom Maleate 36,136 440 36,576 37,616 565 38,181 38,844 609 39,453 38,654 634 39,288 
Levomepromazine 44,307 2,154 46,461 48,899 3,066 51,965 51,414 3,480 54,894 56,810 3,623 60,433 
Midazolam 101,280 4,867 106,147 1,19,379 6,546 125,925 127,087 7,177 134,264 145,067 8,125 153,192 
Morphine Sulfate 348,408 17,088 3,65,496 395,866 23,644 419,510 442,336 30,344 472,680 489,730 41,414 531,144 
Oxycodone 121,007 5,402 1,26,409 130,262 7,499 137,761 141,968 10,219 152,187 154,515 13,698 168,213 
 
Total  
 
1,142,537 50,492 1,193,029 1,256,994 66,653 1,323,647 1,356,781 82,769 1,439,550 1,484,694 106,462 1,591,156 
Percentage of yearly 
total 
 
95.8 4.2 100 95.0 5.0 100 94.3 5.7 100 93.3 6.7 100 
Total increase on 
previous year 
- - - 114,457 16,161 66,653 99,787 16,116 115,903 127,913 23,693 151,606 
Percentage increase 
on previous year 
- - - 10.0 32.0 5.6 7.9 24.2 8.8 9.4 28.6 10.5 
NMP = Non-medical prescriber 
